Compare CIA & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIA | DTIL |
|---|---|---|
| Founded | 1969 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.3M | 197.9M |
| IPO Year | 1995 | 2019 |
| Metric | CIA | DTIL |
|---|---|---|
| Price | $3.45 | $5.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $29.40 |
| AVG Volume (30 Days) | 104.7K | ★ 249.5K |
| Earning Date | 11-05-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $255,616,000.00 | ★ $1,070,000,000.00 |
| Revenue This Year | $0.22 | N/A |
| Revenue Next Year | $4.28 | N/A |
| P/E Ratio | $28.23 | ★ N/A |
| Revenue Growth | ★ 4.33 | N/A |
| 52 Week Low | $3.31 | $3.53 |
| 52 Week High | $6.54 | $9.62 |
| Indicator | CIA | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 42.66 | 36.45 |
| Support Level | $3.39 | $5.35 |
| Resistance Level | $3.73 | $7.55 |
| Average True Range (ATR) | 0.14 | 0.33 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 37.50 | 9.09 |
Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. The company operates in two business segments namely the Domestic Insurance and International Insurance segments.. The company majority generates revenues from Life Insurance segment. Company operates in USA, Columbia, Taiwan, Venezuela, Ecuador, Argentina, and Others.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).